8-K: DocGo Reports 2025 Losses, Raises 2026 Guidance, Explores Strategic Alternatives

DocGo Inc. announced significant losses for 2025 due to migrant program wind-down, but raised its 2026 revenue and adjusted EBITDA guidance while initiating a strategic alternatives review.

Summary

• Total revenue for the full year 2025 was $322.2 million, a decrease from $616.6 million in 2024, primarily due to the wind-down of migrant-related programs.
• The company reported a net loss of $196.4 million for 2025, compared to a net income of $13.4 million in 2024, including $88.8 million in non-cash impairments.
• Adjusted EBITDA for 2025 was a loss of $28.6 million, a significant decline from a positive adjusted EBITDA of $60.3 million in 2024.
• Excluding migrant-related programs, Q4 2025 revenue increased 11% to $67.5 million, and Mobile Health Services revenue (excluding migrant programs) increased 47%.
• DocGo's 'healthcare at any address' business tripled revenue to $12.8 million in Q4 2025, with record volumes across several core business lines.
• The company raised its full-year 2026 revenue guidance to $290-$310 million and improved its adjusted EBITDA loss guidance to $5-$10 million.
• DocGo has initiated a formal process to explore strategic alternatives to maximize shareholder value.
• The company expects to achieve profitability in the second half of 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but cautiously optimistic report. While 2025 financial results were significantly negative due to the migrant program wind-down and impairments, the strong growth in core business lines, raised 2026 guidance, and the initiation of a strategic review provide a positive forward-looking narrative.

Positives

• Raised full-year 2026 revenue guidance to $290-$310 million, an increase from prior guidance of $280-$300 million.
• Improved full-year 2026 adjusted EBITDA loss guidance to $5-$10 million, better than prior guidance of $15-$25 million loss.
• Core 'healthcare at any address' business revenue tripled to $12.8 million in Q4 2025 from $4.3 million in Q4 2024.
• Achieved record volumes in Q4 2025 across US medical transportation (+11%), healthcare in the home (+113%), mobile phlebotomy (+16%), remote patient monitoring (+16%), and virtual care & lab orders (+50%).
• SteadyMD, acquired in October 2025, expanded its clinical workforce and achieved its highest monthly revenue on record in February 2026.
• Expanded relationship with a major national insurance payer to launch a new preventive exams program in Kentucky in March 2026.
• Anticipates additional margin improvements in both Medical Transportation and Mobile Health segments in 2026.
• Expects to achieve profitability in the second half of 2026.

Negatives

• Total revenue for Q4 2025 declined to $74.9 million from $120.8 million in Q4 2024, primarily due to the wind-down of migrant-related programs.
• Full-year 2025 total revenue decreased significantly to $322.2 million from $616.6 million in 2024.
• Reported a net loss of $142.3 million in Q4 2025, a substantial increase from a net loss of $7.6 million in Q4 2024.
• Full-year 2025 net loss was $196.4 million, a reversal from net income of $13.4 million in 2024.
• Adjusted EBITDA was a loss of $11.3 million in Q4 2025, compared to a positive adjusted EBITDA of $1.1 million in Q4 2024.
• Full-year 2025 adjusted EBITDA was a loss of $28.6 million, down from a positive $60.3 million in 2024.
• Included in the 2025 loss were significant non-cash impairments totaling $88.8 million ($30.6 million intangible assets, $58.2 million goodwill, $5 million equity investment).
• GAAP gross margin declined to 27.2% in Q4 2025 from 30.8% in Q4 2024, and to 25.8% for full-year 2025 from 32.1% in 2024.
• Cash and cash equivalents decreased to $68.3 million as of December 31, 2025, from $95.2 million as of September 30, 2025.

Risks

• Impacts related to the recent wind down of migrant-related services.
• Ability to continue as a going concern.
• Ability to maintain its listing on Nasdaq.
• Ability to pursue strategic initiatives to deliver on shareholder value.
• Ability to expand programs with insurance partners, hospital systems, municipalities, and other strategic partners.
• Ability to successfully implement its business strategy, including delivering value to shareholders via buybacks and funding new strategic relationships.
• Ability to establish, maintain, and grow customer relationships.
• Ability to execute projects to the satisfaction of its customers.
• Ability to grow demand for its care gap closure programs and other services.
• Ability to maintain or grow its cash balances.
• Reliance on and ability to maintain its contractual relationships with its healthcare provider partners and other strategic partners.
• Ability to compete effectively in a highly competitive industry, including conditions in the healthcare transportation and mobile health services markets.
• Ability to maintain existing contracts.
• Reliance on government contracts, including changes in government spending on healthcare and other social services.
• Recent revenue growth derived from a small number of large customers.
• Ability to effectively manage its growth.
• Financial performance and future prospects.
• Ability to expand geographically.
• M&A activity and success of its acquisition strategy.
• Ability to retain its workforce and management personnel and successfully manage leadership transitions.
• The availability of healthcare professionals and other personnel.
• Changes in the cost of labor.
• Ability to collect on customer receivables.
• Risks associated with the company's share repurchase program.
• Overall macroeconomic and geopolitical conditions, including the interest rate environment, the inflationary environment, the potential recessionary environment, regional conflict and tensions, financial institution instability, and the ongoing or any future shutdown of the U.S. federal government.
• The ability of the company's suppliers to meet its needs.
• The company's ability to obtain or maintain operating licenses.
• Potential changes in federal, state, or local government policies or priorities.
• Expected impacts of geopolitical instability.
• The company's competitive position and opportunities, including its ability to realize the benefits from its operating model.
• The company's ability to improve gross margins.
• The company's ability to implement and deliver on cost-containment measures and ongoing cost rationalization initiatives.
• Legislative and regulatory actions.
• The impact of legal proceedings and compliance risk.
• Volatility of the stock price.
• The impact on the company's business and reputation in the event of information technology system failures, network disruptions, cyber incidents, or losses or unauthorized access to, or release of, confidential information.
• The company's ability to comply with laws and regulations regarding data privacy and protection.

Future Outlook

DocGo projects full-year 2026 revenue between $290 million and $310 million, an increase from previous guidance, and anticipates an adjusted EBITDA loss of $5 million to $10 million, also an improvement. The majority of this loss is expected in the first half of 2026, with the company targeting profitability in the second half of 2026. This outlook is driven by record volumes, customer expansions, improved EMS hiring rates, and efficiency initiatives, and does not include any migrant-related revenue.

Management Comments

• Lee Bienstock, CEO: "While 2025 was a year of transition and focus on our core business lines, the robust growth in our healthcare at any address business supports our belief that DocGo’s offering is well positioned to meet the needs of the evolving healthcare landscape."
• Lee Bienstock, CEO: "We are increasing guidance based on the record volumes we’ve seen thus far in 2026, and the anticipated full-year impact of our cost efficiency initiatives. We believe that our plan and resources are sufficient to enable the Company to achieve profitability in the second half of 2026."
• Norm Rosenberg, CFO: "I am encouraged by the positive trend in medical transportation gross margins on both a quarterly sequential and year-over-year basis, and we anticipate additional margin improvements in both segments in 2026."
• Norm Rosenberg, CFO: "During the fourth quarter, the company incurred material costs associated with the final wind-down of migrant-related programs, which will not recur in Q1."
• Norm Rosenberg, CFO: "Cash collections during the fourth quarter of 2025 were lower than our expectations, driven by delayed payments from our outstanding migrant-related receivables. We have collected more than 97% of all migrant-related receivables to date, and expect that we will collect the approximately $20 million outstanding in due course."

Industry Context

StockSavvy.ai notes that DocGo's pivot away from high-volume, low-margin migrant-related programs towards its core 'healthcare at any address' and medical transportation services aligns with broader industry trends emphasizing value-based care, remote patient monitoring, and efficient care gap closure. The growth in these segments, particularly virtual care and mobile phlebotomy, reflects increasing demand for accessible, in-home healthcare solutions, a trend accelerated by recent public health shifts. The acquisition of SteadyMD and its expansion into GLP-1 weight loss care also positions DocGo in a rapidly growing and competitive segment of virtual health.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential for increased value through the strategic alternatives review, but current losses and cash burn may cause concern. Raised 2026 guidance and expected profitability in H2 2026 could instill confidence.
• Employees: Expansion of clinical workforce for SteadyMD and improved EMS hiring rates suggest potential for job growth in core areas, but overall cost efficiency initiatives could imply workforce adjustments.
• Customers: Expansion of services, record volumes, and new payer partnerships indicate improved service offerings and reach, particularly in 'healthcare at any address' and virtual care.
• Creditors: Delayed collection of $20 million in migrant-related receivables could impact short-term liquidity, but the company expects collection in due course. Overall cash position has declined.

Next Steps

• Hold a conference call and webcast on March 16, 2026, at 5:00 p.m. Eastern Time to discuss earnings results.
• Continue the formal process to explore strategic alternatives to maximize shareholder value.
• Launch an expanded program with a major national insurance payer in Kentucky in March 2026 to facilitate annual preventive exams and close care gaps.
• Focus on achieving profitability in the second half of 2026.

Key Dates

Recommendation

The company reported significant losses and impairments for 2025, which are concerning. However, the underlying core business shows strong growth, and management has raised its 2026 guidance, projecting a return to profitability in the second half of the year. The initiation of a formal process to explore strategic alternatives introduces a significant unknown that could materially impact future valuation, making a 'hold' recommendation appropriate as investors await further clarity on this strategic review and the company's execution on its improved 2026 outlook.

Keywords

Mobile Health, Medical Transportation, Healthcare Services, Telehealth, Virtual Care, Adjusted EBITDA, Revenue Guidance, Strategic Alternatives, SEC Filing, Earnings Report, DCGO, DocGo